RhumbLine Advisers’s Cytek Biosciences CTKB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $961K | Sell |
282,651
-13,633
| -5% | -$46.4K | ﹤0.01% | 2268 |
|
|
2025
Q1 | $1.19M | Buy |
296,284
+1,745
| +0.6% | +$7K | ﹤0.01% | 2090 |
|
|
2024
Q4 | $1.91M | Buy |
294,539
+14
| +0% | +$91 | ﹤0.01% | 1901 |
|
|
2024
Q3 | $1.63M | Sell |
294,525
-60,911
| -17% | -$337K | ﹤0.01% | 2016 |
|
|
2024
Q2 | $1.98M | Buy |
355,436
+18,124
| +5% | +$101K | ﹤0.01% | 1891 |
|
|
2024
Q1 | $2.26M | Buy |
337,312
+9,682
| +3% | +$65K | ﹤0.01% | 1849 |
|
|
2023
Q4 | $2.99M | Buy |
327,630
+5,638
| +2% | +$51.4K | ﹤0.01% | 1702 |
|
|
2023
Q3 | $1.78M | Buy |
321,992
+31,570
| +11% | +$174K | ﹤0.01% | 1912 |
|
|
2023
Q2 | $2.48M | Buy |
290,422
+141,055
| +94% | +$1.2M | ﹤0.01% | 1787 |
|
|
2023
Q1 | $1.37M | Buy |
149,367
+6,804
| +5% | +$62.5K | ﹤0.01% | 1998 |
|
|
2022
Q4 | $1.46M | Buy |
142,563
+1,845
| +1% | +$18.8K | ﹤0.01% | 1947 |
|
|
2022
Q3 | $2.07M | Buy |
140,718
+11,751
| +9% | +$173K | ﹤0.01% | 1741 |
|
|
2022
Q2 | $1.38M | Buy |
128,967
+32,689
| +34% | +$351K | ﹤0.01% | 1960 |
|
|
2022
Q1 | $1.04M | Buy |
96,278
+81,455
| +550% | +$878K | ﹤0.01% | 2117 |
|
|
2021
Q4 | $242K | Buy |
14,823
+3,062
| +26% | +$50K | ﹤0.01% | 2775 |
|
|
2021
Q3 | $252K | Buy |
+11,761
| New | +$252K | ﹤0.01% | 2836 |
|